Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWJ108J in Prostate Cancer
NCT03029533Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Peak Plasma Concentration at Day 99 and Area under the plasma concentration versus time curve at Day 99. Status: unknown.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03029533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029533.